Literature DB >> 20840314

Association of blood monocyte and lymphocyte count and disease-free interval in dogs with osteosarcoma.

J L Sottnik1, S Rao, M H Lafferty, D H Thamm, P S Morley, S J Withrow, S W Dow.   

Abstract

BACKGROUND: Identification of biomarkers that predict outcomes in dogs with osteosarcoma (OSA) would be valuable to veterinarians and owners. Leukocyte numbers in peripheral blood are associated with outcomes in some types of cancer in humans. HYPOTHESIS/
OBJECTIVES: We hypothesized that increased numbers of monocytes would be associated with reduced disease-free interval (DFI) in dogs with OSA. ANIMALS: Medical data from 69 dogs with appendicular OSA treated with amputation and chemotherapy were selected for study.
METHODS: Retrospective study. Statistical associations were assessed by univariate and multivariate analysis. Information about DFI and leukogram values, tumor location, and serum alkaline phosphatase was abstracted from the medical record.
RESULTS: Higher numbers of circulating monocytes (>0.4×10(3)  cells/μL) and lymphocytes (>1.0×10(3)  cells/μL) before treatment were found to be significantly (P<.05) associated with shorter DFI in dogs with OSA. Other parameters associated with poor outcomes were increased alkaline phosphatase, primary tumor location, and age. CONCLUSION AND CLINICAL IMPORTANCE: These results indicated that pretreatment evaluation of monocyte and lymphocyte counts provided prognostic information for dogs with appendicular OSA. Notably, most animals in this study had monocyte counts within the normal reference range, indicating that variations within the reference range of leukocyte values might also have prognostic significance.
Copyright © 2010 by the American College of Veterinary Internal Medicine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20840314     DOI: 10.1111/j.1939-1676.2010.0591.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  21 in total

1.  Suppression of canine myeloid cells by soluble factors from cultured canine tumor cells.

Authors:  J Wasserman; L Diese; Z VanGundy; C London; W E Carson; T L Papenfuss
Journal:  Vet Immunol Immunopathol       Date:  2011-12-28       Impact factor: 2.046

2.  Role of monocyte recruitment in hemangiosarcoma metastasis in dogs.

Authors:  D P Regan; A Escaffi; J Coy; J Kurihara; S W Dow
Journal:  Vet Comp Oncol       Date:  2016-10-25       Impact factor: 2.613

3.  Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma.

Authors:  Sita S Withers; Katherine A Skorupski; Daniel York; Jin W Choi; Kevin D Woolard; Renee Laufer-Amorim; Ellen E Sparger; Carlos O Rodriguez; Stephen J McSorley; Arta M Monjazeb; William J Murphy; Robert J Canter; Robert B Rebhun
Journal:  Vet Comp Oncol       Date:  2018-09-19       Impact factor: 2.613

4.  Retrospective analysis of use of fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG PET/CT) for detection of metastatic lymph nodes in dogs diagnosed with appendicular osteosarcoma.

Authors:  Powell T Slinkard; Elissa K Randall; Lynn R Griffin
Journal:  Can J Vet Res       Date:  2021-04       Impact factor: 1.310

5.  Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma.

Authors:  Sunetra Das; Rupa Idate; Daniel P Regan; Jared S Fowles; Susan E Lana; Douglas H Thamm; Daniel L Gustafson; Dawn L Duval
Journal:  Commun Biol       Date:  2021-10-11

6.  Osteosarcoma tissues and cell lines from patients with differing serum alkaline phosphatase concentrations display minimal differences in gene expression patterns.

Authors:  L C de Sá Rodrigues; K E Holmes; V Thompson; C M Piskun; S E Lana; M A Newton; T J Stein
Journal:  Vet Comp Oncol       Date:  2015-02-03       Impact factor: 2.613

Review 7.  Manipulation of Innate Immunity for Cancer Therapy in Dogs.

Authors:  Daniel Regan; Steven Dow
Journal:  Vet Sci       Date:  2015-12-01

Review 8.  Prognostic factors in canine appendicular osteosarcoma - a meta-analysis.

Authors:  Ilse Boerman; Gayathri T Selvarajah; Mirjam Nielen; Jolle Kirpensteijn
Journal:  BMC Vet Res       Date:  2012-05-15       Impact factor: 2.741

9.  Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma.

Authors:  Daniel P Regan; Lyndah Chow; Sunetra Das; Laurel Haines; Eric Palmer; Jade N Kurihara; Jonathan W Coy; Alissa Mathias; Douglas H Thamm; Daniel L Gustafson; Steven W Dow
Journal:  Clin Cancer Res       Date:  2022-02-15       Impact factor: 13.801

10.  Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma.

Authors:  L E Selmic; J H Burton; D H Thamm; S J Withrow; S E Lana
Journal:  J Vet Intern Med       Date:  2014-02-10       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.